Pre-emptive treatment helped curtail skin toxicity with panitumumab
Friday, January 16, 2009 - 16:35
in Health & Medicine
With a pre-emptive, prophylactic skin regimen, patients who receive panitumumab for treatment of metastatic colorectal cancer may be able to avoid some of the skin-associated toxicities, according to data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.